licensing agreement
Eisai Licenses Nuvation Bio’s Taletrectinib for ROS1+ Lung Cancer in Europe and Asia
Eisai; Nuvation Bio; taletrectinib; ROS1+ NSCLC; licensing agreement; lung cancer
MacroGenics Stops Bispecific Development; Third Arc Bio Signs $840M Licensing Deal with Adagene
MacroGenics; lorigerlimab; bispecific antibody; mCRPC; clinical trial halt; Third Arc Bio; Adagene; SAFEbody technology; CD3 T cell engagers; licensing agreement; biotech deals
Kowa Secures Expanded Rights to Nicox’s Glaucoma Drug NCX 470 in Major Global Deal
Kowa; Nicox; NCX 470; glaucoma; exclusive rights; licensing agreement; Denali clinical trial; ophthalmology; royalties; milestone payments
GSK’s ViiV Expands Licensing Deal to Increase Access to Long-Acting Injectable HIV Treatment
GSK; ViiV Healthcare; long-acting HIV treatment; cabotegravir; licensing agreement; Medicines Patent Pool; generic manufacturing; HIV; global health
Sanofi Licenses Formation Bio’s JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal
Sanofi; Formation Bio; gusacitinib; JAK/SYK inhibitor; AI drug development; Libertas Bio; deal; chronic hand eczema; new indication; licensing agreement
Kaken Secures Japanese Rights for Alumis’ Novel TYK2 Inhibitor ESK-001
Alumis, Kaken Pharmaceutical, ESK-001, TYK2 inhibitor, dermatology, licensing agreement, Japan
Merck Acquires Rights to Hengrui’s Oral Lp(a) Inhibitor in $2B Deal
Merck, Hengrui Pharmaceuticals, HRS-5346, Lp(a) inhibitor, cardiovascular disease, atherosclerosis, licensing agreement
Merck Secures $2B Deal with China’s Hengrui for Novel Heart Drug
Merck, Hengrui Pharmaceuticals, HRS-5346, Lipoprotein(a) inhibitor, cardiovascular disease, licensing agreement
Servier Acquires Rights to Black Diamond’s Solid Tumor Drug BDTX-4933 in $780M Deal
Servier, Black Diamond Therapeutics, BDTX-4933, solid tumors, licensing agreement, RAS/RAF inhibitor
AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes
AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme